Zhenbao Island announced that the Jixi branch previously submitted a marketing registration application for mabalosavir in April 2025 and was accepted, and recently obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the State Drug Administration. The API showed a status of “A” on the CDE API, pharmaceutical excipients and pharmaceutical packaging materials registration information disclosure platform. Up to now, the company has invested a total of about 8.717,300 yuan in R&D expenses in this R&D project. The API complies with relevant national evaluation technical standards, and can be produced and sold in the domestic market after meeting the requirements of pharmaceutical production quality management standards; the matter will not have a significant impact on the company's current business performance, and there is great uncertainty about drug production and sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.